Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01239901|
Recruitment Status : Active, not recruiting
First Posted : November 15, 2010
Last Update Posted : March 28, 2017
|Condition or disease|
|Sickle Cell Disease|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Iron-mediated Vascular Disease in Sickle Cell Disease.|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||October 2018|
|Estimated Study Completion Date :||October 2018|
- Liver iron concentration (LIC), pancreas R2*, and kidney R2*, measured by MRI [ Time Frame: 15 min MRI done completed during one time study visit ]Liver iron concentration (LIC) will be used as a surrogate for total body iron, pancreatic iron represents a surrogate for extravascular iron deposition, and renal iron as a surrogate for chronic intravascular hemolysis. In addition, labile plasma iron will be measured in blood plasma.
- Vascular function. [ Time Frame: Scheduled during one time study visit ]Measurements will be done through several procedures: Ultrasound of artery in upper arm, Ultrasound of artery in neck, and blood tests of ascorbate and hydrobiopterins.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01239901
|United States, California|
|Children's Hospital Los Angeles|
|Los Angeles, California, United States, 90027|
|Principal Investigator:||John C Wood, MD, PhD||Children's Hospital Los Angeles|